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Abstract
An 82-year-old woman with common bile duct (CBD) dilatation observed during routine ultrasonography was referred
to our hospital. Preliminary blood tests revealed elevated levels of hepatobiliary enzymes. Computed tomography (CT)
scan showed lower bile duct wall thickening and enhancement. Esophagogastroduodenoscopy revealed mildly swollen
papilla of Vater, without ulceration. Endoscopic retrograde cholangiography demonstrated that the CBD was grossly
dilated with a constriction in the lower part. The final diagnosis indicated poorly differentiated adenocarcinoma of
duodenal papilla with signet-ring cells; pT3N0M0, stage IIA (Unio Internationalis Contra Cancrum, 7th edition),
for which subtotal stomach-preserving pancreaticoduodenectomy (SSPPD) was performed. This case is quite rare, and
the surgery resulted in a desirable outcome. The patient has been disease-free for 5 years since the surgery.
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Background
Most duodenal papillary carcinomas (DPCs) are well
differentiated [1]. Poorly differentiated DPCs are rare
and have unfavorable prognosis. Signet-ring cells in the
duodenal papilla are an indication of poor prognosis.
Here, we report a case of poorly differentiated DPC with
signet-ring cells that had favorable outcome.
Case presentation
An 82-year-old woman with common bile duct (CBD)
dilatation, as observed during routine ultrasonography,
was referred to our hospital. She was asymptomatic.
Laboratory test results were aspartate aminotransferase
level, 278 IU/L; alanine aminotransferase level, 184 IU/L;
alkaline phosphatase level, 1877 IU/L; total bilirubin
level, 0.42 mg/dL; amylase level, 47 IU/L; and presence
of routine inflammatory markers. Laboratory tumor
marker levels, carcinoembryonic antigen, and carbohy-
drate antigen 19–9 levels were normal.
Esophagogastroduodenoscopy (EGD) revealed mildly
swollen papilla of Vater, without any mucosal erosion
(Fig. 1).
Dynamic computed tomography (CT) showed bile
duct wall thickening that was enhanced in the lower part
of the CBD (Fig. 2). Endoscopic retrograde cholangiog-
raphy (ERC) demonstrated abrupt obstruction of the
lower CBD (Fig. 3). Histological examination of biopsy
specimens from the lower CBD showed adenocarcinoma
with signet-ring cells. We diagnosed extrahepatic
cholangiocarcinoma and performed subtotal stomach-
preserving pancreaticoduodenectomy (SSPPD). The
surgery lasted 348 min, and the total blood loss was
525 mL. Histopathology report suggested atypical
epithelial cells exhibiting infiltrative growth, with fibrosis
of the duodenal papilla (Fig. 4c). Tumor cells displayed
intracytoplasmic mucus deposition, crescent-shaped
nucleoli (Fig. 4d, e) extensions along the lower CBD, and
invasion of pancreatic parenchyma (3 mm). AcbBd, ex-
posed protruded type, 22 × 16 mm, por2/sig, pT3a, sci,
INFc, ly1, v1, ne1, pN0, pHM0, pPM0, pEM0, PV0, A0,
R0, pStage IIA according to the Japanese Classification
on Cancer of the biliary tract [2] and pT3N0M0 stage
IIA in accordance with Union for Internationatinal
Cancer Control, 7th edition. The final diagnosis was
poorly differentiated adenocarcinoma with signet-ring
cell of DPC. The patient developed pancreatic fistula
postoperatively (ISGPF grade B), with no other
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complications and was discharged on day 37 postsurgery.
She has remained disease-free for 5 years since the surgery.
Discussions
DPC is a rare clinical entity, occurring in less than 6 per
million people annually. It represents 0.2% of all gastro-
intestinal cancers and accounts for only 6% of all cancers
developing in the periampullary region [3]. The Japanese
Society of Hepato-Biliary-Pancreatic Surgery reported
that the most common histological type of DPC is well-
differentiated adenocarcinoma (36.3%), followed by
papillary adenocarcinoma (27.6%) and moderately differ-
entiated adenocarcinoma (25.0%). Poorly differentiated
adenocarcinoma is rare and accounts for 5.5% of all
DPC cases [4]. Signet-ring cells are also extremely
uncommon histologic types at this site and arise mainly
from the stomach. Signet-ring cell carcinomas (SRCC)
are characterized by signet-ring cells with intracytoplas-
mic mucin occupying more than 50% of the tumor [5].
In our case, the proportion of signet-ring cells to whole
carcinoma was about 10–15%, so we diagnosed poorly
differentiated adenocarcinoma with signet-ring cells, and
not SRCC. Furthermore, poorly differentiated DPCs are
rare, and on a PubMed search using key words like
Vater, poorly differentiated, and signet, only ten well-
documented cases were found (Table 1) [6–15]. The
11 cases, including our case, consisted of three men
and eight women with ages ranging from 43 to 83 years
(mean 62 years). Jaundice was the most common
Fig. 1 EGD reveals mildly swollen and protruded papilla of Vater, with
no mucosal erosion. Cancer cells are not found in the biopsy specimen
Fig. 2 Dynamic CT images, arterial phase, a axial view, and b coronal view show thickening of the wall that is enhanced in the lower part of the
CBD (red arrowheads), accompanied by a proximal dilatation of the biliary tract. No lymph node metastases are observed
Fig. 3 Cholangiography demonstrates that CBD was abruptly obstructed
in the lower part (blue arrowheads) and was grossly dilated in
the proximal part
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Fig. 4 a Resected specimen. Macroscopically, there is an exposed protruded tumor (interrupted square). b The cut surface of the duodenal wall
and the pancreatic head (a most anal; c most oral). From a to c, there are whitish tumors (interrupted circles). The scale divisions represent 1 mm
each in a and b. c Histopathologically, the cancer cells show the pancreatic invasion with infiltrative growth and fibrosis. The most parts of the
tumor are poorly differentiated adenocarcinoma, and the ratio of signet-ring cells was about 10–15% (hematoxylin-eosin, ×40, the scale bars indicate
1 mm). d, e Tumor cells contain mucin, which makes the nucleoli crescent-shaped (hematoxylin-eosin, ×600, the scale bars indicate 20 μm)
Table 1 Published cases of poorly differentiated adenocarcinoma in duodenal papilla with signet-ring cells









Chemotherapy Por/sig 12 Died
Eriguchi[6] 2003 83 M Jaundice T3N0M0
stage IIA
– PD Sig 12 Alive
Ramia [7] 2004 67 F Jaundice T2N0M0
stage IB
– PD Sig 12 Alive
Akatsu [8] 2007 43 F Jaundice T2N0M0
stage IB
– PD Sig 90 Alive
Bloomston [9] 2006 58 F Jaundice T2N0M0
stage IB
– PD Sig 134 Alive




– PD Sig 18 Died
Ogata [11] 2010 42 F Jaundice T4N1M0
stage III
– SSPPD Sig 6 Alive




Brain Gross total resection
of brain tumor
Sig 3 Died
Acharya [13] 2013 78 F Jaundice T3N0M0
stage IIA
– PD Sig 6 Alive






PD Sig 7 Alive
Our case 2016 82 F – T3N0M0
stage IIA
– SSPPD Por/sig 60 Alive
aInternational Union Against Cancer TNM classification
bDisseminated intravascular coagulation
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symptom (54.5%). Two cases of DPC with jaundice
survived for more than 5 years after surgery, while rapid
metastasis [13] was observed in others, as was disseminat-
ing carcinomatosis without jaundice [6].
The 5-year survival rate in patients with DPC after
radical resection is 30–68% [16–19]. In most cases, the
prognosis of DPC is better than biliary and pancreatic
carcinomas. Owing to their anatomical location, ampul-
lary tumors become clinically apparent earlier because
of biliary or pancreatic duct occlusion. Since DPC is
often diagnosed at an early stage, surgical resection has
a higher probability of success. The average recurrence
interval of DPC was 13–22 months [19, 20], and recur-
rence includes liver metastasis, local recurrence, periton-
eal metastasis, and bone metastasis [19–21]. The
important factors affecting the prognosis are lymph node
status, depth of tumor invasion, and degree of tumor
differentiation [22, 23]. Patients with pancreatic infiltra-
tion tend to have early recurrences [24]. Lymph node
status is a significant predictive factor in liver metastasis,
and a 5-year survival rate in patients with lymph
node-positive status is 19.1% and of those with node-
negative status is 63.7% [21]. Immunohistochemical
staining patterns of cytokeratin and mucin allow further
classification of SRCC to intestinal, pancreatobiliary, gas-
tric, and mixed type. SRCC patients with intestinal type
are favorable, and those with mixed type reveal poor
prognosis.
In our case, although the tumor consisted of poorly
differentiated adenocarcinoma with signet-ring cells and
had infiltrated into the pancreatic parenchyma pT3, both
of which indicating poor prognosis, the outcome was
desirable. She was diagnosed with DPC incidentally in
the health checkup before having jaundice; therefore, the
ratio of signet-ring cells was relatively low. Similar
reports are very few for DPC [25].
It is well known that surgical resection is the only
curative treatment for DPC. No evidence-based chemo-
therapy regimens exist either for the treatment of unre-
sectable cancers or for postoperative adjuvant therapy;
therefore, we simply followed up the patient. Fortu-
nately, the patient is doing well, without any signs of
tumor recurrence since the last 5 years.
Conclusions
Here, we have presented favorable results in a case of
poorly differentiated DPC with signet-ring cells. It is
however important to study some more cases with simi-
lar outcomes to establish its characteristics.
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